TARRYTOWN, N.Y. -- Regeneron Pharmaceuticals, Inc. (REGN) today announced that EYLEA ® (aflibercept) Injection has received approval for the treatment of patients with neovascular age-related macular ...
Bayer is handing over up to $2.45bn to acquire Perfuse Therapeutics – marking the company’s first bid to enhance its legacy in the ophthalmology market since the patent expiry of its best-selling eye ...
The aflibercept 8 mg injection improves patient care by allowing longer intervals between treatments, explains Jose A. Martinez, MD, Austin Retina Associates. A new Healthcare Common Procedure Coding ...
Regeneron Pharmaceuticals has announced the U.S. FDA's acceptance for Priority Review of the supplemental Biologics License Application for EYLEA HD (aflibercept) Injection 8 mg, which, if approved, ...
There’s a lot of excitement about Roche’s new eye disease drug Vabysmo, which is in-line for “rapid uptake” this year, but it faces an uphill struggle to topple the likes of Regeneron and Bayer’s ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved Eylea for the treatment of retinopathy of prematurity in preterm infants, according to a press ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results